世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

局所薬物デリバリー市場:タイプ毎(半固体、液体、固体、経皮製剤)、経由毎、利用場所毎(家庭、病院、重症熱傷センター) - 2024年までの世界市場予測

Topical Drug Delivery Market by Type (Semisolids (Creams, Ointments, Gels, Lotions), Liquids, Solids, Transdermal Products), Route (Dermal, Ophthalmic, Rectal, Vaginal, Nasal), Facility of Use (Homecare, Hospital, Burn Center) - Global Forecast to 2024

 

出版社 出版年月電子版価格 ページ数図表数
MarketsandMarkets
マーケッツアンドマーケッツ
2019年8月US$5,650
シングルユーザライセンス
189 181

サマリー

幅広い市場に関する調査レポートを出版しているマーケッツアンドマーケッツ(MarketsandMarkets)の局所薬物デリバリー市場に関する調査レポートです。

“The topical drug delivery market is projected to grow at a CAGR of 5.7% during the forecast period (2019-2024).”

The topical drug delivery market is projected to reach USD 123.2 billion by 2024 from USD 93.2 billion in 2019, at a CAGR of 5.7%. The growth of the topical drug delivery market is driven mainly by the high prevalence of skin disease, rising incidences of eye diseases, high incidence of burn injuries, and the growing prevalence of diabetes. Additionally, emerging markets such as China and India are expected to offer potential growth opportunities to market players in the coming years. However, preference for alternative modes of drug delivery such as oral, injectables, pulmonary, among others could restrict the growth of this market.

By product, the semi-solid formulations segment is expected to account for the largest share of the topical drug delivery market

Based on product, the topical drug delivery market is segmented into semi-solid formulations (creams, gels, ointments, pastes, and lotions), solid formulations (suppositories and powders), liquid formulations (solutions and suspensions), and transdermal products (transdermal patches and transdermal semi-solids). The semi-solid formulations segment is expected to account the largest market share of the topical drug delivery market in 2019. This is mainly due to their easy application and ability to topically deliver a wide variety of drug molecules compared to other formulations.

By route of administration, dermal drug delivery segment to dominate the topical drug delivery market during the forecast period

The dermal drug delivery segment accounted for the largest share of the market in 2018. This is mainly due to the high prevalence of skin diseases across the globe. For instance, According to the WHO, between 2 and 3 million cases of non-melanoma skin cancer and 132,000 cases of melanoma skin cancer are diagnosed annually across the globe.

By facility of use, homecare settings segment to dominate the topical drug delivery market during the forecast period

The homecare settings segment accounted for the largest share of the market in 2018. This is mainly due to the ease of use of topical products at home, better affordability, and advantages of topical and transdermal patches for patients who require a constant drug level as well as those suffering from chronic diseases at homecare settings.

“North America is expected to witness the highest growth during the forecast period.”

North America is expected to account for the largest share of the global topical drug delivery market in 2019, followed by Europe. However, Japan is expected to witness the highest CAGR during the forecast period. This can primarily be attributed to the rising geriatric population, increasing the inflow of generic drugs, a growing number of product approvals and launches, and the increasing focus of local players on the R&D of topical formulations in the country. For instance, in November 2018, Santen Pharmaceutical Co., Ltd. (Japan) and Ube Industries (Japan) launched the topical EYBELIS Ophthalmic Solution 0.002% in Japan. Similarly, in September 2018, Santen Pharmaceutical Co., Ltd. (Japan) signed a development and drug discovery agreement with PeptiDerm Inc. (Japan) for developing topical ophthalmic products. Furthermore, in June 2017, LEO Pharma (Denmark) partnered with Kyowa Hakko Kirin Co., Ltd. (Japan) for the development of a topical gel formulation for the treatment of psoriasis.

A breakdown of the primary participants referred to for this report is provided below:

- By Company Type: Tier 1-55%, Tier 2-25%, and Tier 3-20%
- By Designation: C-level-43%, Director-level-32%, and Others-25%
- By Region: North America-38%, Europe-29%, Asia Pacific-23%, Rest of World-10%

The prominent players in the topical drug delivery market are Nestle SA (Switzerland), Johnson & Johnson (US), Bausch Health Companies (Canada), Novartis AG (Switzerland), GlaxoSmithKline (UK), Bayer AG (Germany), Hisamitsu Pharmaceutical (Japan), Mylan (US) Glenmark Pharmaceuticals (India), Cipla Ltd (India), Crescita Therapeutics Inc. (Canada), and Merck & Co (US).

Research Coverage:

The report analyzes the topical drug delivery market and aims at estimating the market size and future growth potential of the topical drug delivery market and the different segments such as dermal, ophthalmic, rectal, vaginal, and nasal drug delivery. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product & service offerings, and recent developments.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a greater share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:

- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the topical drug delivery market.
- Product & Service Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launch in the topical drug delivery market.
- Market Development: Comprehensive information on lucrative emerging regions.
- Market Diversification: Exhaustive information about new products and services, growing geographies, and recent developments in the global topical drug delivery market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products & services of the leading players in the topical drug delivery market.



目次

1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 21
1.3.2 YEARS CONSIDERED FOR THE STUDY 21
1.4 CURRENCY 22
1.5 LIMITATIONS 22
1.6 STAKEHOLDERS 22

2 RESEARCH METHODOLOGY 23
2.1 RESEARCH DATA 23
2.1.1 SECONDARY DATA 25
2.1.1.1 Key data from secondary sources 25
2.1.2 PRIMARY DATA 26
2.1.2.1 Key data from primary sources 27
2.1.2.2 Key industry insights 27
2.2 MARKET SIZE ESTIMATION 28
2.2.1 BOTTOM-UP APPROACH 28
2.2.2 TOP-DOWN APPROACH 28
2.2.3 GROWTH FORECAST 28
2.3 MARKET DATA VALIDATION AND TRIANGULATION 30
2.4 ASSUMPTIONS FOR THE STUDY 31

3 EXECUTIVE SUMMARY 32

4 PREMIUM INSIGHTS 35
4.1 TOPICAL DRUG DELIVERY MARKET OVERVIEW 35
4.2 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2018 36
4.3 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2018 37
4.4 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT 38

5 MARKET OVERVIEW 39
5.1 INTRODUCTION 39
5.2 MARKET DYNAMICS 39
5.2.1 DRIVERS 40
5.2.1.1 High prevalence of skin diseases 40
5.2.1.2 Rising prevalence of eye diseases 40
5.2.1.3 High incidence of burn injuries 40
5.2.1.4 Growing prevalence of diabetes 40
5.2.2 RESTRAINTS 41
5.2.2.1 Preference for alternative modes of drug delivery 41
5.2.3 OPPORTUNITIES 41
5.2.3.1 Delivery of biologics through the transdermal route 41
5.2.3.2 Self-administration and home care 41
5.2.4 CHALLENGES 42
5.2.4.1 Technical barriers related to skin irritation and permeability 42
5.2.4.2 Drug failures and product recalls 43

6 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT 44
6.1 INTRODUCTION 45
6.2 SEMI-SOLID FORMULATIONS 46
6.2.1 CREAMS 47
6.2.1.1 Ease of spreadability and washability to drive this market segment 47
6.2.2 OINTMENTS 48
6.2.2.1 Ointments are widely used in analgesic indications 48
6.2.3 LOTIONS 49
6.2.3.1 Easy administration of lotions to drive their demand among end users 49
6.2.4 GELS 50
6.2.4.1 Faster drug release and greater patient acceptability to drive the market for topical gels 50
6.2.5 PASTES 51
6.2.5.1 Topical pastes are widely used for the treatment and prevention of skin irritation 51
6.3 LIQUID FORMULATIONS 52
6.3.1 SUSPENSIONS 53
6.3.1.1 Higher rate of bioavailability and controlled onset of action to support the growth of the topical suspensions market 53
6.3.2 SOLUTIONS 54
6.3.2.1 Topical solutions comprise soluble chemicals that are dissolved in various solvents 54
6.4 SOLID FORMULATIONS 55
6.4.1 POWDERS 56
6.4.1.1 Powders have a very fine particle size that covers a large surface area per unit weight 56
6.4.2 SUPPOSITORIES 57
6.4.2.1 Suppositories require a suitable base that ensures the compatibility and stability of the drug 57
6.5 TRANSDERMAL PRODUCTS 58
6.5.1 TRANSDERMAL PATCHES 60
6.5.1.1 Transdermal patches to account for the largest share of
the transdermal drug delivery market in 2019 60
6.5.2 TRANSDERMAL SEMI-SOLIDS 63
6.5.2.1 Transdermal semi-solids segment to witness negative growth during the forecast period 63

7 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION 65
7.1 INTRODUCTION 66
7.2 DERMAL DRUG DELIVERY 67
7.2.1 DERMAL DRUG DELIVERY IS THE LARGEST SEGMENT IN THIS MARKET DUE TO ADVANTAGES SUCH AS EASE OF USE AND INCREASED PATIENT COMPLIANCE 67
7.3 OPHTHALMIC DRUG DELIVERY 68
7.3.1 INCREASING USE OF MOBILE DEVICES IS LIKELY TO IMPACT VISION, WHICH IS A KEY FACTOR SUPPORTING MARKET GROWTH 68
7.4 RECTAL DRUG DELIVERY 69
7.4.1 POOR ABSORPTION OF DRUGS THROUGH THE RECTAL ROUTE-A KEY DISADVANTAGE ASSOCIATED WITH THIS MARKET SEGMENT 69
7.5 VAGINAL DRUG DELIVERY 70
7.5.1 HIGH PERMEABILITY OF VAGINAL TISSUES, THE SCOPE OF SELF-ADMINISTRATION, AND EASE OF MANUFACTURING ARE EXPECTED TO BOOST THE GROWTH OF THE VAGINAL DRUG DELIVERY MARKET SEGMENT 70
7.6 NASAL DRUG DELIVERY 71
7.6.1 ABSENCE OF DRUG DEGRADATION, HIGH EFFICACY OF NASALLY ADMINISTERED DRUGS, AND GROWING PREFERENCE FOR SELF-ADMINISTRATION TO DRIVE MARKET GROWTH 71

8 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE 72
8.1 INTRODUCTION 73
8.2 HOME CARE SETTINGS 74
8.2.1 HOME CARE SETTINGS ACCOUNTED FOR THE LARGEST SHARE IN 2018 74
8.3 HOSPITALS AND CLINICS 75
8.3.1 RISING INCIDENCE OF SURGICAL SITE INFECTIONS TO DRIVE THIS SEGMENT 75
8.4 BURN CENTERS 76
8.4.1 HIGH INCIDENCE OF BURN INJURIES ACROSS THE GLOBE TO SUPPORT
THE MARKET GROWTH 76
8.5 OTHER FACILITIES 77

9 TOPICAL DRUG DELIVERY MARKET, BY REGION 78
9.1 INTRODUCTION 79
9.2 NORTH AMERICA 81
9.2.1 US 86
9.2.1.1 Rising prevalence of skin diseases and the approval and launch of innovative topical formulations-key factors driving market growth 86
9.2.2 CANADA 91
9.2.2.1 Rising prevalence of skin diseases and funding for the development of topical drugs to drive market growth 91
9.3 EUROPE 95
9.3.1 GERMANY 101
9.3.1.1 Growing focus of pharmaceutical companies on the development of topical products to drive market growth 101
9.3.2 UK 106
9.3.2.1 Rising prevalence of skin diseases & chronic conditions to drive market growth 106
9.3.3 FRANCE 110
9.3.3.1 Rising prevalence of skin diseases and development of topical drugs by local players to support market growth 110
9.3.4 REST OF EUROPE 114
9.4 ASIA PACIFIC 118
9.4.1 JAPAN 124
9.4.1.1 Increasing number of product approvals and growing focus of local players on the R&D of topical formulations to support market growth 124
9.4.2 CHINA 128
9.4.2.1 Growing focus of major players in China on the development of topical drugs to drive market growth 128
9.4.3 INDIA 132
9.4.3.1 Rising awareness among healthcare providers & patients and increasing focus on noninvasive methods of drug delivery
to drive market growth 132
9.4.4 REST OF ASIA PACIFIC 136
9.5 REST OF THE WORLD 140

10 COMPETITIVE LANDSCAPE 145
10.1 OVERVIEW 145
10.2 MARKET SHARE ANALYSIS 145
10.2.1 JOHNSON & JOHNSON 145
10.2.2 NESTL- SA (GALDERMA) 146
10.2.3 NOVARTIS 146
10.3 COMPETITIVE SCENARIO 146
10.3.1 PRODUCT LAUNCHES 146
10.3.2 EXPANSIONS 147
10.3.3 AGREEMENTS AND COLLABORATIONS 147
10.3.4 ACQUISITIONS 148
10.4 COMPETITIVE LEADERSHIP MAPPING (OVERALL MARKET) (2018) 148
10.4.1 VISIONARY LEADERS 148
10.4.2 INNOVATORS 148
10.4.3 DYNAMIC DIFFERENTIATORS 149
10.4.4 EMERGING COMPANIES 149
-
11 COMPANY PROFILES 150
(Business overview, Products offered, Recent developments, MNM view)*
11.1 GLAXOSMITHKLINE 150
11.2 JANSSEN GLOBAL SERVICES (A SUBSIDIARY OF JOHNSON & JOHNSON) 153
11.3 BAUSCH HEALTH COMPANIES 156
11.4 MERCK & CO. 159
11.5 BAYER AG 161
11.6 HISAMITSU PHARMACEUTICAL 163
11.7 NESTL- SA 166
11.8 NOVARTIS AG 169
11.9 GLENMARK PHARMACEUTICALS 172
11.10 CIPLA 175
11.11 CRESCITA THERAPEUTICS INC. 178
11.12 MYLAN N.V. 180
*Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.

12 APPENDIX 182
12.1 DISCUSSION GUIDE 182
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 185
12.3 RELATED REPORTS 187
12.4 AUTHOR DETAILS 188

 

LIST OF TABLES

TABLE 1 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2024 (USD MILLION) 45
TABLE 2 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 46
TABLE 3 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY COUNTRY, 2017-2024 (USD MILLION) 47
TABLE 4 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY COUNTRY,
2017-2024 (USD MILLION) 48
TABLE 5 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY COUNTRY,
2017-2024 (USD MILLION) 49
TABLE 6 TOPICAL DRUG DELIVERY MARKET FOR LOTIONS, BY COUNTRY,
2017-2024 (USD MILLION) 50
TABLE 7 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY COUNTRY,
2017-2024 (USD MILLION) 51
TABLE 8 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY COUNTRY,
2017-2024 (USD MILLION) 52
TABLE 9 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE,
2017-2024 (USD MILLION) 52
TABLE 10 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2017-2024 (USD MILLION) 53
TABLE 11 TOPICAL DRUG DELIVERY MARKET FOR SUSPENSIONS, BY COUNTRY,
2017-2024 (USD MILLION) 54
TABLE 12 TOPICAL DRUG DELIVERY MARKET FOR SOLUTIONS, BY COUNTRY,
2017-2024 (USD MILLION) 55
TABLE 13 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE,
2017-2024 (USD MILLION) 55
TABLE 14 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2017-2024 (USD MILLION) 56
TABLE 15 TOPICAL DRUG DELIVERY MARKET FOR POWDERS, BY COUNTRY,
2017-2024 (USD MILLION) 57
TABLE 16 TOPICAL DRUG DELIVERY MARKET FOR SUPPOSITORIES, BY COUNTRY,
2017-2024 (USD MILLION) 58
TABLE 17 COMPARISON BETWEEN TRANSDERMAL PATCHES AND TRANSDERMAL
SEMI-SOLID FORMULATIONS 59
TABLE 18 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2024 (USD MILLION) 59
TABLE 19 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2017-2024 (USD MILLION) 60
TABLE 20 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY COUNTRY, 2017-2024 (USD MILLION) 62
TABLE 21 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL SEMI-SOLIDS,
BY COUNTRY, 2017-2024 (USD MILLION) 64
TABLE 22 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION,
2017-2024 (USD MILLION) 66
TABLE 23 DERMAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2024 (USD MILLION) 67
TABLE 24 OPHTHALMIC DRUG DELIVERY MARKET, BY COUNTRY, 2017-2024 (USD MILLION) 68
TABLE 25 RECTAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2024 (USD MILLION) 69
TABLE 26 VAGINAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2024 (USD MILLION) 70
TABLE 27 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2024 (USD MILLION) 71
TABLE 28 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017-2024 (USD MILLION) 73
TABLE 29 TOPICAL DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2017-2024 (USD MILLION) 74
TABLE 30 TOPICAL DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2017-2024 (USD MILLION) 75
TABLE 31 TOPICAL DRUG DELIVERY MARKET FOR BURN CENTERS, BY COUNTRY,
2017-2024 (USD MILLION) 76
TABLE 32 TOPICAL DRUG DELIVERY MARKET FOR OTHER FACILITIES, BY COUNTRY,
2017-2024 (USD MILLION) 77
TABLE 33 TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2024 (USD MILLION) 80
TABLE 34 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2017-2024 (USD MILLION) 82
TABLE 35 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET,
BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 82
TABLE 36 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017-2024 (USD MILLION) 83
TABLE 37 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 83
TABLE 38 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 84
TABLE 39 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 84
TABLE 40 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2024 (USD MILLION) 85
TABLE 41 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017-2024 (USD MILLION) 85
TABLE 42 PRODUCT APPROVALS & LAUNCHES IN THE US MARKET (2017-2019) 87
TABLE 43 US: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION,
2017-2024 (USD MILLION) 88
TABLE 44 US: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2024 (USD MILLION) 88
TABLE 45 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 89
TABLE 46 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 89
TABLE 47 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 90
TABLE 48 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2024 (USD MILLION) 90
TABLE 49 US: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017-2024 (USD MILLION) 91
TABLE 50 CANADA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 92
TABLE 51 CANADA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017-2024 (USD MILLION) 92
TABLE 52 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2017-2024 (USD MILLION) 93
TABLE 53 CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 93
TABLE 54 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 94
TABLE 55 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2017-2024 (USD MILLION) 94
TABLE 56 CANADA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017-2024 (USD MILLION) 95
TABLE 57 RECENT DEVELOPMENTS IN THE EUROPEAN TOPICAL DRUG DELIVERY MARKET, 2015-2018 96
TABLE 58 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2017-2024 (USD MILLION) 98
TABLE 59 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 98
TABLE 60 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017-2024 (USD MILLION) 99
TABLE 61 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2017-2024 (USD MILLION) 99
TABLE 62 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 100
TABLE 63 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 100
TABLE 64 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2017-2024 (USD MILLION) 100
TABLE 65 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017-2024 (USD MILLION) 101
TABLE 66 DEVELOPMENTS IN THE FIELD OF TOPICAL DRUG DELIVERY IN GERMANY,
2017-2019 102
TABLE 67 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 103
TABLE 68 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017-2024 (USD MILLION) 103
TABLE 69 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 104
TABLE 70 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2017-2024 (USD MILLION) 104
TABLE 71 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2017-2024 (USD MILLION) 105
TABLE 72 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2017-2024 (USD MILLION) 105
TABLE 73 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017-2024 (USD MILLION) 106
TABLE 74 DEVELOPMENTS IN THE TOPICAL DRUG DELIVERY MARKET IN THE UK,
2016-2019 107
TABLE 75 UK: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION,
2017-2024 (USD MILLION) 107
TABLE 76 UK: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017-2024 (USD MILLION) 108
TABLE 77 UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 108
TABLE 78 UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 109
TABLE 79 UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 109
TABLE 80 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2024 (USD MILLION) 109
TABLE 81 UK: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017-2024 (USD MILLION) 110
TABLE 82 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 111
TABLE 83 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017-2024 (USD MILLION) 111
TABLE 84 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2017-2024 (USD MILLION) 112
TABLE 85 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 112
TABLE 86 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 113
TABLE 87 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2017-2024 (USD MILLION) 113
TABLE 88 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017-2024 (USD MILLION) 114
TABLE 89 ROE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION,
2017-2024 (USD MILLION) 115
TABLE 90 ROE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017-2024 (USD MILLION) 115
TABLE 91 ROE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2017-2024 (USD MILLION) 116
TABLE 92 ROE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 116
TABLE 93 ROE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 117
TABLE 94 ROE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2024 (USD MILLION) 117
TABLE 95 ROE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017-2024 (USD MILLION) 118
TABLE 96 DEVELOPMENTS IN THE TOPICAL DRUG DELIVERY MARKET IN THE ASIA PACIFIC, 2016-2019 118
TABLE 97 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2017-2024 (USD MILLION) 120
TABLE 98 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 121
TABLE 99 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017-2024 (USD MILLION) 121
TABLE 100 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 122
TABLE 101 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2017-2024 (USD MILLION) 122
TABLE 102 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2017-2024 (USD MILLION) 122
TABLE 103 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017-2024 (USD MILLION) 123
TABLE 104 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017-2024 (USD MILLION) 123
TABLE 105 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION,
2017-2024 (USD MILLION) 125
TABLE 106 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017-2024 (USD MILLION) 125
TABLE 107 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2017-2024 (USD MILLION) 126
TABLE 108 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 126
TABLE 109 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 127
TABLE 110 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2017-2024 (USD MILLION) 127
TABLE 111 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017-2024 (USD MILLION) 128
TABLE 112 CHINA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION,
2017-2024 (USD MILLION) 129
TABLE 113 CHINA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017-2024 (USD MILLION) 129
TABLE 114 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2017-2024 (USD MILLION) 130
TABLE 115 CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 130
TABLE 116 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 131
TABLE 117 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2017-2024 (USD MILLION) 131
TABLE 118 CHINA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017-2024 (USD MILLION) 132
TABLE 119 INDIA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION,
2017-2024 (USD MILLION) 133
TABLE 120 INDIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017-2024 (USD MILLION) 134
TABLE 121 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2017-2024 (USD MILLION) 134
TABLE 122 INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 135
TABLE 123 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 135
TABLE 124 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2017-2024 (USD MILLION) 135
TABLE 125 INDIA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017-2024 (USD MILLION) 136
TABLE 126 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 (USD MILLION) 137
TABLE 127 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017-2024 (USD MILLION) 138
TABLE 128 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2017-2024 (USD MILLION) 138
TABLE 129 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 139
TABLE 130 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017-2024 (USD MILLION) 139
TABLE 131 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2017-2024 (USD MILLION) 139
TABLE 132 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017-2024 (USD MILLION) 140
TABLE 133 ROW: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION,
2017-2024 (USD MILLION) 141
TABLE 134 ROW: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017-2024 (USD MILLION) 142
TABLE 135 ROW: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
 BY TYPE, 2017-2024 (USD MILLION) 142
TABLE 136 ROW: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS MARKET,
BY TYPE, 2017-2024 (USD MILLION) 143
TABLE 137 ROW: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS MARKET,
BY TYPE, 2017-2024 (USD MILLION) 143
TABLE 138 ROW: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS MARKET, BY TYPE, 2017-2024 (USD MILLION) 143
TABLE 139 ROW: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017-2024 (USD MILLION) 144
TABLE 140 PRODUCT LAUNCHES 146
TABLE 141 EXPANSIONS 147
TABLE 142 AGREEMENTS AND COLLABORATIONS 147
TABLE 143 ACQUISITIONS 148

 

LIST OF FIGURES

FIGURE 1 TOPICAL DRUG DELIVERY MARKET SEGMENTATION 21
FIGURE 2 TOPICAL DRUG DELIVERY MARKET: RESEARCH METHODOLOGY 23
FIGURE 3 RESEARCH DESIGN 24
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 26
FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 29
FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 29
FIGURE 7 DATA TRIANGULATION METHODOLOGY 30
FIGURE 8 TOPICAL DRUG DELIVERY MARKET SHARE, BY PRODUCT, 2018 32
FIGURE 9 TOPICAL DRUG DELIVERY MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2018 33
FIGURE 10 TOPICAL DRUG DELIVERY MARKET SHARE, BY FACILITY OF USE, 2018 33
FIGURE 11 GEOGRAPHIC SNAPSHOT: TOPICAL DRUG DELIVERY MARKET, 2018 34
FIGURE 12 HIGH PREVALENCE OF SKIN DISEASES AND HIGH INCIDENCE OF BURN INJURIES TO DRIVE THE GROWTH OF THE TOPICAL DRUG DELIVERY MARKET 35
FIGURE 13 SEMI-SOLID FORMULATIONS TO DOMINATE THE NORTH AMERICAN MARKET DURING THE FORECAST PERIOD 36
FIGURE 14 HOME CARE SETTINGS TO DOMINATE THE EUROPEAN MARKET DURING
THE FORECAST PERIOD 37
FIGURE 15 US TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 38
FIGURE 16 TOPICAL DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 39
FIGURE 17 SEMI-SOLID FORMULATIONS SEGMENT TO COMMAND THE LARGEST SHARE OF THE MARKET IN 2019 45
FIGURE 18 DERMAL DRUG DELIVERY TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 66
FIGURE 19 HOME CARE SETTINGS SEGMENT TO COMMAND THE LARGEST SHARE OF
THE MARKET IN 2019 73
FIGURE 20 TOPICAL DRUG DELIVERY MARKET, BY REGION, 2019 VS. 2024 79
FIGURE 21 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET SNAPSHOT 81
FIGURE 22 EUROPE: TOPICAL DRUG DELIVERY MARKET SNAPSHOT 97
FIGURE 23 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET SNAPSHOT 120
FIGURE 24 REST OF THE WORLD: TOPICAL DRUG DELIVERY MARKET SNAPSHOT 141
FIGURE 25 MARKET SHARE ANALYSIS BY KEY PLAYERS (2018) 145
FIGURE 26 TOPICAL DRUG DELIVERY MARKET (GLOBAL) COMPETITIVE LEADERSHIP
MAPPING, 2018 149
FIGURE 27 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT 150
FIGURE 28 JOHNSON & JOHNSON: COMPANY SNAPSHOT 153
FIGURE 29 BAUSCH HEALTH COMPANIES: COMPANY SNAPSHOT 156
FIGURE 30 MERCK & CO.: COMPANY SNAPSHOT 159
FIGURE 31 BAYER AG.: COMPANY SNAPSHOT 161
FIGURE 32 HISAMITSU PHARMACEUTICAL: COMPANY SNAPSHOT 163
FIGURE 33 NESTL- SA: COMPANY SNAPSHOT 166
FIGURE 34 NOVARTIS AG: COMPANY SNAPSHOT 169
FIGURE 35 GLENMARK PHARMACEUTICALS: COMPANY SNAPSHOT 172
FIGURE 36 CIPLA: COMPANY SNAPSHOT 175
FIGURE 37 CRESCITA THERAPEUTICS: COMPANY SNAPSHOT (2018) 178
FIGURE 38 MYLAN: COMPANY SNAPSHOT (2018) 180

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る